Since miR-181b-abundant glioma cells is more sensitive to temozolomide (TMZ) [21], aplysin enhances TMZ action through increasing the expression of miR-181 in TMZ-resistant glioma cells, which results in MEK1 (mitogen-activated protein kinase kinase 1) downregulation [22]. Here, MAP3K1 is linked to central nervous system cancer.